Corcept Therapeutics Incorporated (CORT) Stock Price & Analysis

Corcept Therapeutics Incorporated (CORT) closed at USD 107.5 on Thursday, October 22, 2026, down 7.55% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 116.28; the Oct 22, 2026 session ranged USD 107.33–115.73 on volume of 809,797 shares. Market capitalization is $11.62B, with a 52-week range of USD 28.66–126.38 (NCM). Source: Nexqual, retrieved October 23, 2026 at 10:37 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CORT.md

Key facts (CORT)

• Last four reported quarters (through Jun 30, 2026): revenue $831M, net income $55.2M (6.6% margin), free cash flow $107M (SEC filings).
• Valuation: P/E 210.6x (avg 38.9x at the last 3 fiscal year-ends).
• Earnings quality: non-operating income $20.0M vs operating income $6.4M over the last four quarters; P/E excluding non-operating income ≈330.0x (estimate: non-operating income taxed at the company's 0% effective rate).
• Analysts: Buy (mean 2.20 on a 1–5 scale) (5 analysts), mean target USD 141 (range 50–165).
• Total return with dividends: 1Y +47.3% vs S&P 500 +14.9%; 5Y +474.3% vs S&P 500 +80.3%.
• Next earnings: 2026-11-04, EPS estimate USD 0.84, revenue estimate $336M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CORT)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CORT)

P/E 210.6x · P/E ex non-operating (est.) ≈330.0x · P/S 14.0x · P/FCF 108.7x · P/B 16.5x · FCF yield 0.92% · Earnings yield 0.47% · Buyback yield (TTM) 0.37%

P/E at fiscal year-ends: Dec 2025 41.9x, Dec 2024 40.5x, Dec 2023 34.2x.

Analysts (CORT)

Consensus Buy (mean 2.20 on a 1–5 scale), 5 analysts; mean target USD 141 (low 50, high 165).

Rating changes, last 120 days:

Total return (dividends reinvested) (CORT)

CORT revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

CORT suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

CORT customer concentration

In the period ended Dec 31, 2025, a single direct customer accounted for 1% of revenue, per the company's 10-K filed Feb 24, 2026. The company does not name it.

CORT company outlook (results filed Jul 29, 2026)

• “We anticipate continued strength across our businesses and have increased our 2026 revenue guidance to $1.1 – $1.2 billion," said Joseph K.”
• “We expect a decision on our NDA by December 17, 2026.”
• “In addition, results from MONARCH, our Phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), are expected by the end of this year.”
• “We look forward to building on these promising findings in our Phase 2b MONARCH study, with results expected by the end of this year," said Dr.”

Analysts expect $336.4M for the current quarter, 70.8% below the midpoint of the company's guidance ($1.15B).

Quoted word-for-word from the SEC 8-K results press release.

CORT analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 10:37 UTC)

Technical Analysis (CORT)

Nexqual's technical model rates CORT "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:37 UTC.

Analyst Ratings (CORT)

Wall Street analysts rate CORT "Buy" based on 5 analysts, with a mean price target of USD 141 (range USD 50–165), per Nexqual as of October 23, 2026 at 10:37 UTC.

Earnings (CORT)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:37 UTC.

Financials & Fundamentals (CORT)

Source: Nexqual, October 23, 2026 at 10:37 UTC.

Financial Health Score (CORT)

Nexqual rates Corcept Therapeutics Incorporated's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:37 UTC.

Ownership (CORT)

Source: Nexqual, October 23, 2026 at 10:37 UTC.

Leadership (CORT)

Corcept Therapeutics Incorporated is led by Joseph K. Belanoff, Co-Founder, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:37 UTC.

Major Backers & Investors (CORT)

Notable institutional backers of Corcept Therapeutics Incorporated include Ingalls & Snyder LLC, Renaissance Technologies, Parallel Advisors, LLC, according to Nexqual as of October 23, 2026 at 10:37 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:37 UTC.

From Corcept Therapeutics Incorporated's Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• In December 2024, we submitted a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism.
• The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy ("REMS"), to assure the safe use of the product.
• We are developing our proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
• We are testing the potential of our proprietary, selective cortisol modulator, nenocorilant to treat cancer by reducing cortisol-activated immune suppression and thereby help the patient's immune system reduce or eradicate tumors while they receive immunotherapy.

Partnerships

• In June 2025, we notified Optime that it would cease to be our exclusive specialty pharmacy and in October 2025, we delivered a notice of termination of our agreement with them, effective January 8, 2026.
• In collaboration with the Paris-based academic research cooperative ARCAGY-GINECO, we will initiate, in the first quarter of 2026, a Phase 2 trial, STELLA, in 50 patients with cervical cancer, who have received one or two prior lines of therapy.

Legal & Regulatory Risks (Item 1A, quoted)

• New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for our Products, which would adversely affect our results of operations and financial position.
• We may not be able to secure, maintain or effectively assert patent protection for the composition, manufacture, or methods of use of our proprietary, selective cortisol modulators and for the use of our Products to treat hypercortisolism. Litigation is slow and expensive and its outcome is uncertain and subject to challenge on appeal.
• We may be subject to civil or criminal penalties if our marketing of our Products violates FDA regulations or health care fraud and abuse laws.
• We may be unable to obtain or maintain regulatory approvals for our Products or product candidates, which would prevent us from commercializing our product candidates.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:37 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt